A 6 year experience with the St. Jude medical valve: hemodynamic performance, surgical results, biocompatibility and follow-up

After in vitro testing (confirmed in vivo) of three contemporary valve designs (St. Jude, Bjork-Shiley and Carpentier-Edwards) demonstrated that the St. Jude valve possessed the most favorable hydrodynamic performance characteristics, a limited clinical trial was begun in high risk patients who might benefit from a prosthesis with improved hemodynamics. Between March 1978 and March 1984, 419 St. Jude prostheses (157 aortic, 156 mitral and 53 double aortic-mitral) were implanted in 366 patients. Ninety-six percent were in New York Heart Association functional class III or IV preoperatively. Early (30 day) mortality was 10.4% overall, and was lower after aortic (5.7%) or double (7.5%) than after isolated mitral valve replacement (16.0%). Forty-four prosthetic mitral valve recipients with severe ischemic mitral regurgitation experienced a 32% early mortality rate; without this group, mitral valve replacement carried a 10% early mortality rate (p less than 0.01). Multivariate logistic regression analysis confirmed that early death was strongly associated with three preoperative patient characteristics (p less than 0.05): ischemic mitral valve disease, depressed left ventricular function (ejection fraction less than 0.55) and advanced functional class (class IV). Late follow-up (7,055 patient-months, mean 22) was 99.7% complete (1 patient lost). Actuarial survival at 4 years was 80, 80 and 79% after aortic, mitral (nonischemic) and double valve replacement, respectively; in the subset with ischemic mitral regurgitation, actuarial survival was 34% (p less than 0.01). Eighty-six percent of survivors were in functional class I or II.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				I. Gregoric, J. L. Conger, H. Reul, D. Tamez, F. J. Clubb Jr, R. F. Stainback, A. Hernandez, R. Cervera, K. Eya, D. Byler, et al. Preclinical assessment of a trileaflet mechanical valve in the mitral position in a calf model Ann. Thorac. Surg., January 1, 2004; 77(1): 196 - 202. [Abstract] [Full Text] [PDF]

				K. Ananthasubramaniam, J. N. Beattie, H. S. Rosman, V. Jayam, and S. Borzak How Safely and for How Long Can Warfarin Therapy Be Withheld in Prosthetic Heart Valve Patients Hospitalized With a Major Hemorrhage? Chest, February 1, 2001; 119(2): 478 - 484. [Abstract] [Full Text] [PDF]

				B. Chakraborty, S. Quek, Ding Zee Pin, Chee Tek Siong, Tan Ley Kheng, and B. Chakraborty Evaluation of Normal Hemodynamic Profile of Carbomedics Prosthetic Valves by Doppler Echocardiography Angiology, December 1, 1997; 48(12): 1055 - 1061. [Abstract] [PDF]

				W. Vongpatanasin, L. D. Hillis, and R. A. Lange Prosthetic Heart Valves N. Engl. J. Med., August 8, 1996; 335(6): 407 - 416. [Full Text] [PDF]

				D. N. Rosenthal, A. H. Friedman, C. S. Kleinman, G. S. Kopf, L. E. Rosenfeld, and W. E. Hellenbrand Thromboembolic Complications After Fontan Operations Circulation, November 1, 1995; 92(9): 287 - 293. [Abstract] [Full Text]